New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2012
12:08 EDTARNA, PCLN Stocks with call strike movement; PCLN ARNA
Priceline.com (PCLN) May 800 call volatility increased 9%, Arena Pharmaceuticals (ARNA) May 3 call volatility increased 4% according to iVolatility.
News For PCLN;ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
09:58 EDTPCLNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:18 EDTPCLNPriceline initiated with a Neutral at Guggenheim
Subscribe for More Information
05:36 EDTPCLNBooking.com implements new parity provisions in Germany
Subscribe for More Information
May 11, 2015
19:15 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTARNAArena Pharmaceuticals reports Q1 EPS (10c), consensus (14c)
Subscribe for More Information
16:22 EDTARNAArena Pharmaceuticals enters collaboration with Roivant Sciences
Arena Pharmaceuticals announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin. Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and neuropsychiatric disturbances, including psychoses, in patients with dementia and other neurological diseases. In addition, Roivant may pursue the development of nelotanserin for other neuropsychiatric disorders. Roivant will be responsible for funding the development and commercialization of nelotanserin. Under the agreement, Arena will manufacture clinical supply and commercial product to sell to Roivant. Arena will receive a $4.0M upfront payment and is eligible to receive $41.5M in regulatory and development milestone payments. Arena is also eligible to receive 15% of net sales of nelotanserin in exchange for the manufacture and supply of finished commercial drug product, and up to a total of $60.0M in one-time purchase price adjustment payments tied to certain commercial sales milestones.
May 8, 2015
09:02 EDTPCLNPriceline acquires PriceMatch
Priceline acquired PriceMatch, a cloud-based data and analytics solution for hotels. Terms of the deal have not been disclosed. PriceMatch will be integrated into BookingSuite, a recently-launched division of Booking.com.
07:38 EDTPCLNJefferies puts Google atop list of potential Yelp buyers
Jefferies laid out potential buyers for Yelp (YELP) after the Wall Street Journal reported that the company hired bankers to explore a sale. A Google (GOOG, GOOGL), Yelp (YELP) combination makes the most sense, the firm believes. It points out Google unsuccessfully tried to buy Yelp for $550M in 2009. Other potential buyers include Facebook (FB), Priceline (PCLN), GrubHub (GRUB) and Yahoo (YHOO), the firm notes. Jefferies views Yelp as a highly valuable asset and keeps a Buy rating on the stock with a $79 price target. Deutsche Bank today pegged the chances of a Yelp buyout at 60% and estimates a takeout price between $59 and $85 per share. The stock closed yesterday up $8.79 to $47.01 following the Journal's report.
07:19 EDTPCLNDeutsche Bank sees 60% probability of Yelp takeover
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use